<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title> Design and Evaluation of Bayesian Clinical Trials</title>

<script src="site_libs/header-attrs-2.28/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cerulean.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/pagedtable-1.1/css/pagedtable.css" rel="stylesheet" />
<script src="site_libs/pagedtable-1.1/js/pagedtable.js"></script>
<link href="site_libs/font-awesome-6.4.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Zehui Bai</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">
    <span class="fa fa-home"></span>
     
    Home
  </a>
</li>
<li>
  <a href="02-Clinical_Experience.html">
    <span class="fa fa-user"></span>
     
    Clinical Experience
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-sliders"></span>
     
    Sample Size
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="03-SSC-Everything-to-Know-About-Sample-Size-Determination.html">Everything to Know About Sample Size Determination</a>
    </li>
    <li>
      <a href="03-SSC-Choosing-the-Effect-Size-for-Sample-Size-Calculations.html">Choosing the Effect Size</a>
    </li>
    <li>
      <a href="03-SSC-Biosimilar-Trials.html">Statistical Considerations for the Design and Analysis of Biosimilar Trials</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-and-Power-for-Non-Parametric-Analysis.html">Sample Size and Power for Non-Parametric Analysis</a>
    </li>
    <li>
      <a href="03-SSC-Power-for-Complex-Hypotheses.html">Power for Complex Hypotheses</a>
    </li>
    <li>
      <a href="03-SSC-Alternatives-to-Power.html">Bayesian methods - Alternatives to Power</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-for-Pilot-Studies.html">Sample Size for Pilot Studies</a>
    </li>
    <li>
      <a href="03-SSC-Case-Continuous-Endpoint.html">Sample Size Determination for Continuous Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Categorical-Endpoint.html">Sample Size Determination for Categorical Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Survival-Endpoint.html">Sample Size Determination for Survival Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Repeated-Measures.html">Sample Size Determination for Repeated Measures</a>
    </li>
    <li>
      <a href="03-SSC-IA-Sequential-Design.html">Statistical Considerations for Group Sequential Design</a>
    </li>
    <li>
      <a href="03-SSC-IA-Adaptive-Design.html">Statistical Considerations for Adaptive Design</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-pencil-square-o"></span>
     
    Study Design
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="04-Design-Estimands-Framework.html">Estimands Framework</a>
    </li>
    <li>
      <a href="04-Design-Estimands-Practice.html">Estimands and Sensitivity Analyses</a>
    </li>
    <li>
      <a href="04-Design-Phase-I-Trials---Design-Considerations.html">Phase I Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-II-Trials---Design-Considerations.html">Phase II Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-III-Trials---Design-Considerations.html">Phase III Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-IV-Trials---Design-Considerations.html">Phase IV Trials - Design Considerations for Post Marketing Surveillance</a>
    </li>
    <li>
      <a href="04-Design-Complex-Sequential-Trials.html">Complex Sequential Analysis Trials</a>
    </li>
    <li>
      <a href="04-Design-Adaptive-Clinical-Trials.html">Adaptive Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Bayesian-Clinical-Trials.html">Bayesian Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Dose-Escalation-and-Stratification-Designs.html">Dose Escalation and Stratification Designs in Early Oncology Development</a>
    </li>
    <li>
      <a href="04-Design-Single-Arm-Clinical-Trials.html">Single Arm Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Diagnostic-Study-Design-and-Evaluation.html">Diagnostic Study-Design and Evaluation</a>
    </li>
    <li>
      <a href="04-Design-Diagnostic-Study-MRMC.html">Diagnostic Study-Multireader Multicase (MRMC)</a>
    </li>
    <li>
      <a href="04-Design-Hierarchical-composite-endpoints.html">Hierarchical Composite Endpoints</a>
    </li>
    <li>
      <a href="04-Design-Externally-Controlled-Trials.html">Considerations for the Design and Conduct of Externally Controlled Trials</a>
    </li>
    <li>
      <a href="04-Design-Noninferiority-Trials.html">Noninferiority Trials</a>
    </li>
    <li>
      <a href="04-Design-Bioequivalence-and-Biosimilar-Trials.html">Bioequivalence and Biosimilar Trials</a>
    </li>
    <li>
      <a href="04-Design-Exploring-Survival-Analysis-Designs-for-Clinical-Trials.html">Exploring Survival Analysis Designs for Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Projecting-How-Long-Your-Trial-Will-Take.html">Projecting How Long Your Trial Will Take</a>
    </li>
    <li>
      <a href="04-Design-Regulatory-Submission.html">Regulatory Submission from Stats Perspective</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Data Visualization
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="05-Plot-Adverse-Event.html">Adverse Event Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Laboratory-Data.html">Laboratory Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Time-To-Event.html">Time to Event Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-PRO-Data.html">Patient Reported Outcome Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-SSC-and-Power-Calculation.html">Sample Size and Power Calculations Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Correlation.html">Correlation Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Model-Table.html">Clinical Data and Model visualization</a>
    </li>
    <li>
      <a href="05-Plot-ScatterPlot.html">Scatter and Line Plot</a>
    </li>
    <li>
      <a href="05-Plot-BarPlot.html">Bar Chart</a>
    </li>
    <li>
      <a href="05-Plot-PieChart.html">Pie Chart</a>
    </li>
    <li>
      <a href="05-Plot-BoxPlot.html">Box Plot</a>
    </li>
    <li>
      <a href="05-Plot-Histogram.html">Histogram</a>
    </li>
    <li>
      <a href="05-Plot-Forest-Plot.html">Forest Plot</a>
    </li>
    <li>
      <a href="05-Plot-Flow-Chart.html">Flow Chart</a>
    </li>
    <li>
      <a href="05-Plot-Some-Interesting.html">Some Interesting Plots</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-calculator"></span>
     
    Statistical Analysis
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="06-Analysis-Linear-Regression.html">Linear Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Logistic-Regression.html">Logistic Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Mixed-Model.html">Mixed Model</a>
    </li>
    <li>
      <a href="06-Analysis-MMRM.html">Mixed Model Repeated Measures</a>
    </li>
    <li>
      <a href="06-Analysis-GEE.html">Generalized Estimating Equation</a>
    </li>
    <li>
      <a href="06-Analysis-ANOVA.html">Analysis of Variance</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Analysis.html">Survival Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Competing-Risk.html">Survival Analysis - Competing Risk</a>
    </li>
    <li>
      <a href="06-Analysis-Missing-Data.html">Missing Data Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-MI-Implementation.html">Multiple Imputation Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Meta-Analysis.html">Meta Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-PK-and-PD.html">PK and PD Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Time-Series-Analysis.html">Time Series Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-SEM.html">Structural Equation Modeling</a>
    </li>
    <li>
      <a href="06-Analysis-Factor-Analysis.html">Factor Analysis</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-bar-chart"></span>
     
    Machine Learning
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="07-ML-Bayesian-Theory.html">Bayesian Theory</a>
    </li>
    <li>
      <a href="07-ML-Bayesian-Analysis.html">Bayesian Analysis</a>
    </li>
    <li>
      <a href="07-ML-Regularization-Penalized-Regression.html">Regularization Penalized Regression</a>
    </li>
    <li>
      <a href="07-ML-Loss-Regression.html">Loss Functions in Machine Learning</a>
    </li>
    <li>
      <a href="07-ML-PCA.html">Principal Component Analysis</a>
    </li>
    <li>
      <a href="07-ML-KNN.html">K-Nearest Neighbors</a>
    </li>
    <li>
      <a href="07-ML-SVM.html">Support Vector Machine</a>
    </li>
    <li>
      <a href="07-ML-Tree-Models.html">Tree Models</a>
    </li>
    <li>
      <a href="07-ML-LDA.html">Linear Discriminant Analysis</a>
    </li>
    <li>
      <a href="07-ML-Cluster-Analysis.html">Cluster Analysis</a>
    </li>
    <li>
      <a href="07-ML-Neural-Networks.html">Neural Network</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="08-CV.html">
    <span class="fa fa-file-pdf-o"></span>
     
    CV
  </a>
</li>
<li>
  <a href="mailto:zehuibai@outlook.com">
    <span class="fa fa-envelope-o"></span>
     
    Contact me
  </a>
</li>
<li>
  <a href="https://github.com/Zehuibai">
    <span class="fa fa-github"></span>
     
    GitHub
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore"><p><img src="logo.png"
style="width:3in" /><br />
Design and Evaluation of Bayesian Clinical Trials</p></h1>

</div>


<div id="introduction" class="section level1">
<h1>Introduction</h1>
<div id="bayesian-clinical-trials-overview" class="section level2">
<h2>Bayesian Clinical Trials Overview</h2>
<p>Bayesian analysis is a statistical methodology where prior knowledge
about a parameter, denoted as θ, is updated based on new data to form a
posterior distribution. This process involves three key components:</p>
<ul>
<li><strong>Prior</strong>: The initial belief about the parameter
before new data is considered.</li>
<li><strong>Likelihood</strong>: The probability of observing the data
given a parameter value.</li>
<li><strong>Posterior Distribution</strong>: The updated belief about
the parameter after considering the new data. It is calculated using
Bayes’ theorem:</li>
</ul>
<p><span class="math display">\[ P(\theta | D) = \frac{P(D | \theta)
\times P(\theta)}{P(D)} \]</span></p>
<p>where: - <span class="math inline">\(P(\theta | D)\)</span> is the
posterior probability of the parameter given the data. - <span
class="math inline">\(P(D | \theta)\)</span> is the likelihood of the
data given the parameter. - <span
class="math inline">\(P(\theta)\)</span> is the prior probability of the
parameter. - <span class="math inline">\(P(D)\)</span> is the
probability of the data, serving as a normalizing constant.</p>
<p><strong>Advantages of Bayesian Analysis</strong></p>
<ul>
<li><strong>Flexibility</strong>: Bayesian methods can incorporate prior
knowledge, which can be particularly useful in areas with previous
research or expert consensus.</li>
<li><strong>Intuitiveness</strong>: It provides a probabilistic
interpretation that is often more intuitive for decision making.</li>
<li><strong>Integration of Priors</strong>: Allows seamless integration
of external information through priors, which can be especially powerful
in complex models.</li>
</ul>
</div>
<div id="application-in-clinical-trials" class="section level2">
<h2>Application in Clinical Trials</h2>
<ul>
<li><strong>Phase I Trials</strong>: Bayesian methods are replacing
traditional “3+3” dose-escalation designs, as they allow for more
nuanced decision-making processes, including considerations of both
toxicity and efficacy (e.g., determining MTD and OBD).</li>
<li><strong>Phase II Trials</strong>: There is a growing use of Bayesian
methods, which are well suited for adaptive designs such as Simon’s
two-stage design and extensions like BOP2 (Biased Coin Design for Phase
II). These designs facilitate interim analyses that can adjust the trial
based on accumulating data, enhancing efficiency and potentially
reducing patient exposure to ineffective treatments.</li>
<li><strong>Phase III Trials</strong>: Interest in Bayesian methods is
expanding to include more complex elements like seamless Phase II/III
designs, where data from Phase II can be directly used to inform the
conduct and continuation into Phase III.</li>
</ul>
<p>The use of Bayesian methods is also growing in areas involving more
complex statistical considerations, such as:</p>
<ul>
<li><strong>Real-World Data</strong>: Leveraging post-market data to
inform ongoing clinical decisions.</li>
<li><strong>Bayesian Frameworks</strong>: Integration with Bayesian
frameworks to address complex modeling challenges and facilitate
borrowing information across similar trials, enhancing the robustness
and efficiency of the analyses.</li>
</ul>
</div>
</div>
<div id="phase-i-trials-enhancing-dose-escalation-designs"
class="section level1">
<h1>Phase I Trials: Enhancing Dose-Escalation Designs</h1>
<p>In Phase I clinical trials, Bayesian methods are increasingly used to
replace the traditional “3+3” dose-escalation design. The “3+3” design,
which traditionally enrolls groups of three patients at increasing dose
levels until toxicity is observed, offers limited flexibility and often
insufficient exploration of the dose-response curve. Bayesian approaches
provide a more sophisticated framework that considers both toxicity and
efficacy metrics more dynamically:</p>
<ul>
<li><strong>MTD (Maximum Tolerated Dose)</strong>: Bayesian methods can
integrate historical data and current trial results to update beliefs
about the toxicity profile of a drug dynamically. This helps in more
accurately identifying the MTD, where the probability of severe toxicity
remains within an acceptable range.</li>
<li><strong>OBD (Optimal Biological Dose)</strong>: Unlike traditional
methods that primarily focus on toxicity, Bayesian techniques also
evaluate efficacy data to estimate the dose that achieves the best
therapeutic effect with acceptable toxicity. This is particularly useful
in oncology, where the balance between efficacy and toxicity is
critical.</li>
</ul>
<p>The Bayesian framework allows for continuous data monitoring and
adjustment of hypotheses about dose safety and efficacy, which can lead
to quicker decisions about dose adjustments, potentially speeding up the
trial process and improving patient safety.</p>
</div>
<div id="phase-ii-trials-adapting-with-interim-analyses"
class="section level1">
<h1>Phase II Trials: Adapting with Interim Analyses</h1>
<p>In Phase II, Bayesian methods are well-suited for adaptive designs,
which are crucial for making go/no-go decisions based on interim data.
This adaptability reduces resource expenditure and patient exposure to
potentially ineffective treatments:</p>
<ul>
<li><strong>Simon’s Two-Stage Design</strong>: Traditionally used for
determining if a treatment has sufficient activity to warrant further
study, the Bayesian adaptation allows for modifications based on accrued
data at interim points. This could include early stopping for success if
the treatment effect is clearly beneficial or stopping for futility if
the effect is not as expected.</li>
<li><strong>BOP2 (Biased Coin Design for Phase II)</strong>: This method
introduces a probability mechanism that adjusts the likelihood of
continuing the trial based on interim results. It’s designed to be more
responsive and efficient than fixed designs, allowing for a better
balance between type I and type II errors.</li>
</ul>
<p>These adaptive designs enable more flexible and efficient testing of
hypotheses and quicker adaptations to new data, enhancing the overall
development process.</p>
</div>
<div id="phase-iii-trials-seamless-integration-of-phases"
class="section level1">
<h1>Phase III Trials: Seamless Integration of Phases</h1>
<p>Bayesian methods in Phase III trials are increasingly used to
facilitate seamless designs, where data from an earlier phase (like
Phase II) directly informs the conduct of the trial as it moves into
Phase III:</p>
<ul>
<li><strong>Seamless Phase II/III Designs</strong>: These designs treat
phases II and III as a continuum, where promising results from the
intermediate analysis of Phase II can lead directly into expanded Phase
III studies without the need for separate initiation processes. This
approach can significantly shorten the timeline from development to
market approval.</li>
</ul>
<p>Bayesian statistics support these designs by providing a
methodological framework to update the trial parameters based on
cumulative data. This enables ongoing trials to adapt based on interim
outcomes, potentially leading to more efficient resource use and faster
decision-making regarding the drug’s efficacy and safety.</p>
<div id="limited-use-in-bayesian-phase-iii-trials"
class="section level2">
<h2>Limited Use in Bayesian Phase III Trials</h2>
<ul>
<li><strong>Reasons for Rarity</strong>: Bayesian methods are less
common in Phase III trials primarily due to unfamiliarity, lack of
specific regulatory guidance, and stringent statistical requirements,
such as maintaining a Type I error rate at 0.025. This traditional
threshold poses challenges in a Bayesian context where probabilities are
updated as data accumulates.</li>
</ul>
<p><strong>Recent Uptick in Bayesian Application</strong></p>
<ul>
<li><strong>Examples of Bayesian Usage</strong>: There has been an
increase in the use of Bayesian methods in Phase III trials across
various diseases:
<ul>
<li><strong>COVID-19 Vaccine</strong>: Employed Bayesian Sequential
Design, which allows for more flexible and quicker decision-making.</li>
<li><strong>Lymphoma and Psoriasis</strong>: Utilized External Control
Arms (ECA) where historical control data is used to enhance the
statistical power or to replace missing control groups.</li>
<li><strong>Pediatric Multiple Sclerosis and Epilepsy</strong>:
Techniques such as borrowing from adult data (extrapolation) and using
data from similar but distinct patient groups (borrowing) are used to
enhance the robustness of findings and address small patient
populations.</li>
</ul></li>
</ul>
<p><strong>Draft FDA Guidance by 2025</strong></p>
<ul>
<li><strong>Draft FDA Guidance</strong>: Expected by the end of 2025
under PDUFA VII (Prescription Drug User Fee Act), which will address
Bayesian methodology in clinical trials of drugs and biologics.</li>
<li><strong>Adaptive Guidance Principles</strong>: The guidance is
anticipated to align with adaptive trial design principles, advocating
for pre-specification, early engagement, and the use of simulations to
validate trial designs.</li>
<li><strong>Common Use Cases and Success Stories</strong>: The guidance
may include examples of successful Bayesian applications in early-stage
trials, particularly Phase I, and provide an overview of common use
cases such as data borrowing, interim analysis, and adaptations based on
cumulative data.</li>
<li><strong>Key Assessment Criteria</strong>: In Phase III, while an
open approach is expected, there will be a strong emphasis on justifying
the value and maintaining traditional statistical rigor, including Type
I error and power considerations. Specific Bayesian success criteria
might be proposed, such as setting explicit posterior probability
thresholds.</li>
<li><strong>Value in Specific Areas</strong>: Bayesian methods are seen
as particularly valuable in areas like rare diseases and pediatrics,
where patient populations are small, and traditional trial designs might
not be feasible.</li>
<li><strong>Decision-Theoretic Measures</strong>: Although less common,
there might be discussions on integrating decision-theoretic approaches
to measure the success probabilities of treatments, reflecting a more
nuanced and sponsor-oriented consideration.</li>
</ul>
</div>
</div>
<div id="reference" class="section level1">
<h1>Reference</h1>
<div id="bayesian-trials" class="section level2">
<h2>Bayesian Trials</h2>
<p>Ionan, A.C., Clark, J., Travis, J., Amatya, A., Scott, J., Smith,
J.P., Chattopadhyay, S., Salerno, M.J. and Rothmann, M., 2023. Bayesian
methods in human drug and biological products development in CDER and
CBER. Therapeutic Innovation &amp; Regulatory Science, 57(3),
pp.436-444. McElreath, R., 2020. Statistical Rethinking: A Bayesian
Course with Examples in R and STAN. New York: Chapman; Hall/CRC Berry,
D.A., 2006. Bayesian clinical trials. Nature reviews Drug discovery,
5(1), pp.27-36. Berry, S.M., Carlin, B.P., Lee, J.J. and Muller, P.,
2010. Bayesian adaptive methods for clinical trials. CRC press. Lee,
J.J. and Yin, G., 2021. Principles and reporting of Bayesian trials.
Journal of Thoracic Oncology, 16(1), pp.30-36. Muehlemann, N., Zhou, T.,
Mukherjee, R., Hossain, M.I., Roychoudhury, S. and Russek-Cohen, E.,
2023. A tutorial on modern Bayesian methods in clinical trials.
Therapeutic Innovation &amp; Regulatory Science, 57(3), pp.402-416. U.S.
Food and Drug Administration, Guidance for the Use of Bayesian
Statistics in Medical Device Clinical Trials, February 2010 Available
from: <a href="https://www.fda.gov/media/71512/download"
class="uri">https://www.fda.gov/media/71512/download</a></p>
</div>
<div id="early-stage-bayesian-trials" class="section level2">
<h2>Early Stage Bayesian Trials</h2>
<p>Kurzrock, R., Lin, C.C., Wu, T.C., Hobbs, B.P., Pestana, R.C. and
Hong, D.S., 2021. Moving beyond 3+ 3: the future of clinical trial
design. American Society of Clinical Oncology Educational Book, 41,
pp.e133-e144. Zhou, H., Yuan, Y., &amp; Nie, L., 2018. Accuracy, safety,
and reliability of novel phase I trial designs. Clinical Cancer
Research, 24(18), 4357-4364. Liu, M., Wang, S.J. and Ji, Y., 2020. The
i3+ 3 design for phase I clinical trials. Journal of biopharmaceutical
statistics, 30(2), pp.294-304. Lin, X. and Ji, Y., 2020. The Joint i3+ 3
(Ji3+ 3) design for phase I/II adoptive cell therapy clinical trials.
Journal of Biopharmaceutical Statistics, 30(6), pp.993-1005. Cheung, Y.
K., 2011. Dose Finding by the continual reassessment method. CRC Press.
Yan, F., Mandrekar, S.J. and Yuan, Y., 2017. Keyboard: a novel Bayesian
toxicity probability interval design for phase I clinical trials.
Clinical Cancer Research, 23(15), pp.3994-4003. Zhou, Y., Lin, R., Kuo,
Y. W., Lee, J. J., &amp; Yuan, Y., 2021. BOIN Suite: A Software Platform
to Design and Implement Novel Early-Phase Clinical Trials. JCO Clinical
Cancer Informatics, 5, 91-101. Zhou, Y., Li, R., Yan, F., Lee, J.J. and
Yuan, Y., 2021. A comparative study of Bayesian optimal interval (BOIN)
design with interval 3+ 3 (i3+ 3) design for phase I oncology
dose-finding trials. Statistics in biopharmaceutical research, 13(2),
pp.147-155. Yuan, Y., Lee, J.J. and Hilsenbeck, S.G., 2019.
Model-assisted designs for early-phase clinical trials: simplicity meets
superiority. JCO Precision Oncology, 3, pp.1-12. Thall, P.F. and Simon,
R., 1994. Practical Bayesian guidelines for phase IIB clinical trials.
Biometrics, pp.337-349. Zhou, H., Lee, J. and Yuan, Y., 2017. BOP2:
Bayesian Optimal Design for Phase II Clinical Trials with Simple and
Complex Endpoints. Statistics in Medicine, 36, 3302-3314. Woodcock J.,
LaVange LM., 2017. Master Protocols to Study Multiple Therapies,
Multiple Diseases, or Both, N Engl J Med, 377:62-70 Zhou, T. and Ji, Y.,
2024. Bayesian Methods for Information Borrowing in Basket Trials: An
Overview. Cancers, 16(2), p.251. Ouma, L.O., Wason, J.M., Zheng, H.,
Wilson, N. and Grayling, M., 2022. Design and analysis of umbrella
trials: Where do we stand?. Frontiers in Medicine, 9, p.1037439.
Freidlin, B. and Korn, E.L., 2013. Borrowing information across
subgroups in phase II trials: is it useful?. Clinical Cancer Research,
19(6), pp.1326-1334. Beall, J., Cassarly, C. and Martin, R., 2022.
Interpreting a Bayesian phase II futility clinical trial. Trials, 23(1),
p.953.</p>
</div>
<div id="confirmatory-bayesian-trials" class="section level2">
<h2>Confirmatory Bayesian Trials</h2>
<p>Ruberg, S.J., Harrell Jr, F.E., Gamalo-Siebers, M., LaVange, L., Jack
Lee, J., Price, K. and Peck, C., 2019. Inference and decision making for
21st-century drug development and approval. The American Statistician,
73(sup1), pp.319-327. Medical Outreach Subteam of the Drug Information
Association Bayesian Scientific Working Group, Clark, J., Muhlemann, N.,
Natanegara, F., Hartley, A., Wenkert, D., Wang, F., Harrell, F.E. and
Bray, R., 2022. Why are not there more Bayesian clinical trials?
Perceived barriers and educational preferences among medical researchers
involved in drug development. Therapeutic Innovation &amp; Regulatory
Science, pp.1-9. Medical Outreach Team of the Drug Information
Association Bayesian Scientific Working Group, Bray, R., Hartley, A.,
Wenkert, D., Muehlemann, N., Natanegara, F., Harrell Jr, F.E., Wang, F.
and Clark, J., 2023. Why are there not more Bayesian clinical trials?
Ability to interpret Bayesian and conventional statistics among medical
researchers. Therapeutic Innovation &amp; Regulatory Science, 57(3),
pp.426-435. Ruberg, S.J., Beckers, F., Hemmings, R., Honig, P., Irony,
T., LaVange, L., Lieberman, G., Mayne, J. and Moscicki, R., 2023.
Application of Bayesian approaches in drug development: starting a
virtuous cycle. Nature Reviews Drug Discovery, 22(3), pp.235-250. Lee,
S.Y., 2024. Using Bayesian statistics in confirmatory clinical trials in
the regulatory setting: a tutorial review. BMC Medical Research
Methodology, 24(1), p.110. Garczarek, U., Muehlemann, N., Richard, F.,
Yajnik, P. and Russek-Cohen, E., 2023. Bayesian strategies in rare
diseases. Therapeutic Innovation &amp; Regulatory Science, 57(3),
pp.445-452. Senn, S., 2022. The design and analysis of vaccine trials
for COVID‐19 for the purpose of estimating efficacy. Pharmaceutical
Statistics, 21(4), pp.790-807. U.S. Food and Drug Administration, CID
Case Study: External Control in Diffuse B-Cell Lymphoma, Available from:
<a href="https://www.fda.gov/media/155405/download"
class="uri">https://www.fda.gov/media/155405/download</a> U.S. Food and
Drug Administration, CID Case Study: A Study in Pediatric Patients with
Multiple Sclerosis, Available from: <a
href="https://www.fda.gov/media/172313/download"
class="uri">https://www.fda.gov/media/172313/download</a> U.S. Food and
Drug Administration, CID Case Study: A Study in Patients with Epilepsy
with Myoclonic-Atonic Seizures, Available from: <a
href="https://www.fda.gov/media/172312/download"
class="uri">https://www.fda.gov/media/172312/download</a> You, R.,
Weber, S., Bieth, B. and Vandemeulebroecke, M., 2022. Innovative
pediatric development for secukinumab in psoriasis: faster patient
access, reduction of patients on control. Clinical Pharmacology &amp;
Therapeutics, 111(3), pp.697-704. U.S. Food and Drug Administration,
PDUFA VII Commitment Letter, August 2021. Available from: <a
href="https://www.fda.gov/media/151712/download"
class="uri">https://www.fda.gov/media/151712/download</a> Zhou, T.,
&amp; Ji, Y., 2023. On Bayesian Sequential Clinical Trial Designs. The
New England Journal of Statistics in Data Science, 2(1), 136-151.</p>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
